2seventy bio Q1 2025 10-Q Filed
| Field | Detail |
|---|---|
| Company | 2seventy Bio, Inc. |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
2seventy bio Q1 2025 10-Q is in. Revenue and equity details for the quarter are now public.
AI Summary
2seventy bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported revenue from services and royalty income, with specific figures for the first quarter of 2025 and 2024. The filing also details changes in equity accounts like common stock and retained earnings over the same periods.
Why It Matters
This filing provides investors with the latest financial performance and position of 2seventy bio, Inc. for the first quarter of 2025, crucial for understanding ongoing operations and strategic direction.
Risk Assessment
Risk Level: medium — As a biotech company, 2seventy bio faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the sector.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the beginning of the financial quarter being reported.)
- 2024-12-31 — Prior Year End Date (Provides a comparison point to the previous fiscal year-end.)
Key Players & Entities
- 2seventy bio, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- 2025-01-01 (date) — Start of the reporting period
- 2024-12-31 (date) — Previous year-end
FAQ
What were the total revenues for the first quarter of 2025?
The filing indicates revenue from services and royalty income for the period January 1, 2025, to March 31, 2025, but specific dollar amounts are not provided in this header information.
How did the company's equity change during the first quarter of 2025?
The filing details changes in common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings for the period from January 1, 2025, to March 31, 2025.
What is the company's primary industry classification?
2seventy bio, Inc. is classified under Pharmaceutical Preparations [2834].
When was this 10-Q filing submitted?
This 10-Q filing was submitted on May 7, 2025.
What is the company's principal business address?
The business address is 60 BINNEY STREET, CAMBRIDGE, MA 02210.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding 2seventy bio, Inc..